Detalles de la búsqueda
1.
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients.
Breast Cancer Res Treat
; 206(1): 195-205, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38709373
2.
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study.
Breast Cancer Res
; 24(1): 61, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36096872
3.
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Breast Cancer Res
; 22(1): 2, 2019 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31892336
4.
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Br J Cancer
; 120(2): 247-255, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563991
5.
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
Breast Cancer Res
; 18(1): 39, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036195
6.
Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.
Breast Cancer Res
; 17: 35, 2015 Mar 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25888249
7.
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Breast Cancer Res
; 16(3): R68, 2014 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-24981670
8.
ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.
PLoS Genet
; 7(4): e1001382, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21552322
9.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Lancet Oncol
; 14(11): 1067-1076, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24035531
10.
Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Proc Natl Acad Sci U S A
; 107(51): 22231-6, 2010 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-21127264
11.
Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers.
Nat Commun
; 14(1): 4017, 2023 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37419892
12.
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor-positive Breast Cancers.
Clin Cancer Res
; 28(6): 1217-1228, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965950
13.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
EBioMedicine
; 83: 104205, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35985932
14.
Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development.
Int J Cancer
; 127(6): 1486-92, 2010 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20087860
15.
PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
Int J Cancer
; 126(5): 1121-31, 2010 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19685490
16.
High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype.
Histopathology
; 56(3): 286-96, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20459529
17.
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Clin Cancer Res
; 26(3): 608-622, 2020 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31591187
18.
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment.
JCO Precis Oncol
; 32019.
Artículo
en Inglés
| MEDLINE | ID: mdl-32914010
19.
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
Cancer Res
; 66(15): 7401-4, 2006 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16885334
20.
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor-Positive Breast Cancer.
JNCI Cancer Spectr
; 2(2): pky005, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31360844